Allostera has seven Allosteramers™ in its pipeline with a focus on inflammatory diseases. Allostera has one orally active lead Allosteramer™: APG2305 an IL23R inhibitor for autoimmune diseases.
Allostera also has products in development against other inflammation targets including an oral IL1R inhibitor and an oral TNFR inhibitor.
May 19, 2010: Allostera Pharma Inc. Appoints Christopher Henney as Chairman of its Board Of Directors
July 8, 2009: Allostera Pharma Inc. Closes $17M (CAD) Series A Financing
Allostera Pharma Inc.
500 Boul Cartier Ouest
Suite 135
Laval, QC H7V 5B7 Canada
TEL +1 (450) 781-0479
FAX +1 (514) 371-4440
General Information:
info@allostera.com
Business Development Inquiries:
cnicolino@allostera.com
R&D Inquiries:
sbarney@allostera.com